Publication | Closed Access
Effect of Calcium Channel Blocking Agents on Infarct Size After Ischaemia-Reperfusion in Anaesthetised Pigs
17
Citations
0
References
1991
Year
Heart FailureCardiovascular PharmacologyPharmacotherapyCoronary Artery LadCerebral Vascular RegulationAcute Myocardial InfarctionThrombosisInfarct Size DevelopmentPorcine MyocardiumCardiologyAtherosclerosisIschemic SyndromeMyocardial InfarctionAnaesthetised PigsMedicineVascular BiologyCerebral Blood FlowReperfusion InjuryPharmacologyInfarct SizeCardiovascular DiseasePhysiologyAnesthesiaStrokeAnesthesiology
We compared the abilities of verapamil and nicardipine to protect the porcine myocardium from the consequences of ischaemia-reperfusion in vivo. Infusion of verapamil (50 micrograms/kg) into the left anterior descending coronary artery LAD (i.c.a.), in 15 min immediately before ligation depressed regional contractile function, reduced infarct size by 80%, and enabled contractile function to recover partially during reperfusion. Verapamil (10 micrograms/kg i.c.a.) did not depress contractile function before ligation or permit its recovery during reperfusion, despite reducing infarct size by 80%. Lower doses of verapamil were not cardioprotective. Nicardipine (10 and 30 micrograms/kg i.c.a.) depressed contractile function before ligation but did not permit its recovery during reperfusion. Nicardipine did not reduce infarct size development. Thus, drug-induced negative inotropic activity (which presumably reflects myocardial calcium channel blockade) and cardioprotection are not linked. Verapamil can markedly reduce infarct size development at a dose that exerts no detectable negative inotropic activity. This cardioprotective effect of verapamil was greatly reduced by intravenous (i.v) pretreatment with aspirin (30 mg/kg), which alone did not alter infarct size development. Thus, the cardioprotective effect of verapamil (10 micrograms/kg i.c.a.) appears to be mediated by a cyclooxygenase product, possibly prostacyclin.